Feature | Heart Valve Technology | June 30, 2015

Initial Enrollments Made in REDUCE FMR Clinical Trial for Carillon Mitral Repair Device

Blinded, randomized clinical trial evaluating mitral valve repair device in patients with functional mitral regurgitation

REDUCE FMR, Cardiac Dimensions, Carillon Mitral Contour System, FMR

June 30, 2015 - Cardiac Dimensions announced the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a prospective, double-blind, randomized multi-center trial, evaluating the company's minimally-invasive Carillon Mitral Contour System.

Involving up to 20 leading hospitals in Europe and Australia, REDUCE FMR will randomize 120 patients and is designed to establish Carillon as the gold standard treatment for functional mitral regurgitation (FMR) - a condition in which blood flow to the body is reduced due to an abnormally enlarged mitral valve. All patients enrolled in the study are on an optimized heart failure medication regimen and are then randomized into two groups: one additionally treated with the Carillon device and the second remaining on an optimized regimen of heart failure medications, the present gold standard.

The study design contains some unique elements aimed at optimizing recruitment and enrollment, including a 3:1 randomization ratio allowing for more data to be collected with the Carillon device and a crossover registry which allows control patients to receive Carillon treatment at the end of their 12-month follow up. A built-in exercise echocardiographic sub-study will further evaluate the device's ability to reduce mitral regurgitation, improve functional capacity and quality of life as well as induce reverse ventricular remodeling in a symptomatic heart failure patient population both at rest and during exercise.

The REDUCE FMR clinical trial follows three successful multi-center studies, featuring the Carillon device – the AMADEUS, TITAN and TITAN II trials. "My experiences with Carillon have been extremely positive. As an investigator in the last two multi-center trials involving the Carillon therapy I've seen significant clinical improvement in patients who receive the device," said Janusz Lipiecki, M.D., of Clinique Pí´le Santé République in Clermont Ferrand, France. "In this latest landmark trial, we expect to firmly establish the magnitude of benefit that patients receive from Carillon."

The Carillon Mitral Contour System is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart's venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of FMR.

For more information: www.cardiacdimensions.com

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init